^
Association details:
Biomarker:FGFR1 mutation
Cancer:Solid Tumor
Drug:zotatifin (eFT226) (eIF4A1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

Published date:
11/24/2021
Excerpt:
In solid tumor models driven by alterations in HER2 or FGFR1/2, downregulation of oncoprotein expression by zotatifin induces sustained pathway-dependent anti-tumor activity resulting in potent inhibition of cell proliferation, induction of apoptosis, and significant in vivo tumor growth inhibition or regression.
DOI:
10.3389/fonc.2021.766298